Document is current
Any future updates will be listed below
-
Authors
Levey, Daniel F. https://orcid.org/0000-0001-8431-9569
Galimberti, Marco https://orcid.org/0000-0001-6052-156X
Deak, Joseph D. https://orcid.org/0000-0002-0540-6080
Wendt, Frank R.
Bhattacharya, Arjun
Koller, Dora https://orcid.org/0000-0002-0415-0466
Harrington, Kelly M.
Quaden, Rachel
Johnson, Emma C. https://orcid.org/0000-0003-0394-777X
Gupta, Priya
Biradar, Mahantesh https://orcid.org/0000-0002-4114-6255
Lam, Max https://orcid.org/0000-0002-4256-7844
Cooke, Megan
Rajagopal, Veera M. https://orcid.org/0000-0002-5236-168X
Empke, Stefany L. L.
Zhou, Hang
Nunez, Yaira Z.
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
Edenberg, Howard J. https://orcid.org/0000-0003-0344-9690
Agrawal, Arpana https://orcid.org/0000-0002-0313-793X
Smoller, Jordan W.
Lencz, Todd https://orcid.org/0000-0001-8586-338X
Hougaard, David M. https://orcid.org/0000-0001-5928-3517
Børglum, Anders D. https://orcid.org/0000-0001-8627-7219
Demontis, Ditte https://orcid.org/0000-0001-9124-2766
,
Gaziano, J. Michael
Gandal, Michael J. https://orcid.org/0000-0001-5800-5128
Polimanti, Renato https://orcid.org/0000-0003-0745-6046
Stein, Murray B. https://orcid.org/0000-0001-9564-2871
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (AA026364)
U.S. Department of Veterans Affairs (I01CX001849)
Brain and BehaviorResearch Foundation
- License Information
-
More Information
Article History
Received: 26 June 2023
Accepted: 9 October 2023
First Online: 20 November 2023
Competing interests
: H.R.K. is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Clearmind Medicine and Enthion Pharmaceuticals; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi and Otsuka. J.G. and H.R.K. are holders of US patent 10,900,082 titled: ‘Genotype-guided dosing of opioid agonists’, issued 26 January 2021. R.P. and J.G. are paid for their editorial work on the journal <i>Complex Psychiatry</i>. R.P. reports a research grant from Alkermes. The remaining authors declare no competing interests.
